Gossamer Bio GOSS 深 滬
等待開盤 09-25 09:30:00 美东时间
10.93
-0.060
-0.55%
華盛通- 最 高11.679
- 今 開10.76
- 成交量 23.63万股
- 最 低 10.75
- 昨 收 10.99
- 總市值 6685.22万
- 52周最高 309.60
- 市盈率 靜 --
- 換手率 3.86%
- 52周最低 9.104
- 委 比 97.99%
- 總股本 611.64万
- 歷史最高 2172.00
- 量 比 0.69
- 振 幅 8.45%
- 歷史最低 9.104
- 每 手 1
- 風險率 100.07%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Gossamer Bio submits NDA for seralutinib for pulmonary arterial hypertension
Gossamer Bio (GOSS) has submitted an NDA to the US FDA seeking approval of seralutinib for pulmonary arterial hypertension (PAH). The application is supported by data from the phase 3 PROSERA study, e...
09-24 06:16
美股大行评级 | 麦当劳目标价遭下调至320美元！现价仍有近3成上涨空间；戴尔、迈威尔、微软齐获机构看好
今日重点评级关注：HC Wainwright & Co.：维持Gossamer Bio"买入"评级，目标价从2美元升至90美元；巴克莱：维持Ultragenyx Pharmaceutical"超配"评级，目标价从32美元升至35美元
09-22 16:25
Gossamer Bio Defendants Move to Dismiss Securities Lawsuit Over PROSERA Trial Disclosures
Gossamer Bio, Inc. ($GOSS) and two of its executives have asked a federal court...
09-17 17:54
Gossamer Bio Announces 1-For-80 Reverse Stock Split, Effective September 10
Gossamer Bio, Inc. (NASDAQ:GOSS) (the "Company" or "Gossamer"), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, today ...
09-09 21:07
Gossamer Bio announces up to $250M private placement
Gossamer Bio (GOSS) announced on Friday a private placement expected to provide up to approximately $250M in gross proceeds. The financing includes $150M of committed capital, with approximately $25M ...
08-21 21:19
Gossamer Bio Secures Major Seralutinib Regulatory Financing Deal
Gossamer Bio ( ($GOSS) ) has shared an announcement. On August 20, 2026, Gossam...
08-21 20:29
美股大行评级 | 富国上调闪迪目标价从1400美元升至1550美元；塔吉特、Workday、应用材料等获多家大行上调目标价
今日重点评级关注：富瑞：维持ProMIS Neurosciences"买入"评级，目标价从69美元升至100美元；Benchmark：维持Cineverse"买入"评级，目标价从12美元升至14美元
08-17 13:37
Piper Sandler Maintains Overweight on Gossamer Bio, Lowers Price Target to $4
Piper Sandler analyst Yasmeen Rahimi maintains Gossamer Bio (NASDAQ:GOSS) with a Overweight and lowers the price target from $15 to $4.
08-15 00:35
Gossamer Bio Q2 EPS $(0.08) Beats $(0.12) Estimate, Sales $9.238M Beat $5.193M Estimate
Gossamer Bio (NASDAQ:GOSS) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.12) by 33.33 percent. This is a 52.94 percent increase over losses of $(0.17) per share from the same period last year. The company reported quarterly sales of $9.238 million wh...
08-14 04:18
美股大行评级 | 潜在涨幅129.15%！HC Wainwright & Co.升Q32 Bio(QTTB)目标价至36美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Q32 Bio"买入"评级，目标价从13美元升至36美元；Chardan Capital：维持ProMIS Neurosciences"买入"评级，目标价从20美元升至33美元
07-29 11:37
